TuHURA Biosciences (HURA)

• Market cap: $93.8M
• 1 day: 2.47%
• 5 days: 46.9%
• 1 month: 162.82%
• 3 months: -17%
• 6 months: -42.76%
• Year to date: 121.48%
• 1 year: -34.13%
• 5 years: -99.95%
• 10 years: -100%
• Sector: Healthcare
• Industry: Biotechnology

About: TuHURA Biosciences Inc is a Phase 3 registration stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. The company's personalized cancer vaccine candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. It is preparing to initiate a single randomized placebo-controlled Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda (pembrolizumab) in first-line treatment for advanced or metastatic Merkel Cell Carcinoma.

Employees: 19